Supriya Lifescience Q3 FY26: ₹206 Cr Revenue, 35% OPM, 27% ROCE — API Machine or Margin Mirage?
1. At a Glance – The Anti-Histamine King With a 35% Margin Swagger
Supriya Lifescience Ltd is currently trading at ₹710 with a market cap of ₹5,710 crore. The stock has corrected about 9.7% in the last three months — clearly the market had a mild allergic reaction. But the business? Still breathing comfortably.
Q3 FY26 revenue came in at ₹206 crore, up 11% YoY. PAT stood at ₹50 crore. EBITDA clocked ₹72 crore. OPM remains a juicy 35%. ROCE is 27.5%, ROE 20.8%, and the company is practically debt-free with just ₹5.23 crore borrowings. Debt-to-equity? 0.00. Interest coverage? 135 times. That’s not coverage — that’s overkill.
Stock P/E is 30.8 vs industry median ~29.8. Not cheap. Not crazy. Somewhere between confident and slightly arrogant.
Exports contribute ~80% of revenue. Capacity utilization in Q3 FY26 was 76%. And 77% of revenue in Q3 came from backward-integrated products.
So the question is simple.
Is this a niche API powerhouse quietly compounding? Or is it an expensive molecule with concentration risk hiding under shiny margins?
Let’s open the lab.
2. Introduction – From Molecule Maker to Margin Magician
Supriya Lifescience is not a glamorous formulation company selling tablets with Bollywood endorsements.
It makes APIs — Active Pharmaceutical Ingredients. The chemical backbone of drugs. The stuff that actually works while the brand name gets the credit.
They produce 40+ APIs across antihistamines, analgesics, anesthetics, vitamins, anti-asthmatics and more. Historically, three molecules — ketamine, chlorpheniramine, and salbutamol — contributed over 55% of revenue.
That’s concentration risk.
And management knows it.
So they’re launching 3–4 new APIs annually to diversify revenue and reduce molecule dependency. Classic pharma strategy: spread the chemistry before chemistry spreads you.
Revenue for FY25 stood at ₹696 crore. TTM sales ₹735 crore. Five-year sales CAGR 17%. Profit CAGR 21% (5 years), but only 7% over 3 years.
Translation?
The hyper-growth phase cooled down.
But margins improved again in FY25 — OPM at 37%.
Exports across 120 countries. 1,500 customers. Top 10 customers contribute ~45% of revenue. Still concentrated, but manageable.
So now the real question:
Is Supriya scaling sustainably? Or just enjoying one good molecule cycle?
Let’s decode the business.
3. Business Model – WTF Do They Even Do?
Supriya makes APIs. That’s it. No fancy branded drugs. No marketing armies. Just chemistry, reactors, and compliance files.
They operate from Lote Parshuram, Maharashtra, with five manufacturing blocks. Recently commissioned Module E increased capacity by over 55% — from 597 KLPD to 932 KLPD.
That’s serious expansion.
They follow backward integration for 15 products. Meaning they produce key intermediates in-house. Result?
Higher margins. Better cost control. Less dependency on suppliers.
In Q3 FY25, 77% revenue came from integrated products. That’s why margins look like they went to gym.
They also have:
15 DMFs
9 CEPs granted (+4 in process)
18 USDMFs filed (+2 in progress)
4 process patents filed
This is not a local chemical mixer. This is regulatory-compliant global API supplier.
Now they’re setting up an FDF (formulation) facility at Ambernath to move up the value chain. Tablets, capsules, sterile forms.
Ah.
The classic API-to-formulation evolution.
Question: Will they become a full pharma company? Or stick to high-margin niche APIs?
Also WHO-GMP certification for Ambernath inhalation facility in Oct 2025.
Regulatory credibility? Checked.
But APIs are cyclical. Molecules peak. Then normalize.
Are we at peak cycle?
Let’s check the numbers.
4. Financials Overview – The Q3 FY26 Chemistry Report
EPS: Jun 2025: ₹4.32 Sep 2025: ₹6.27 Dec 2025: ₹6.17
